推荐产品
重組細胞
expressed in E. coli
品質等級
形狀
liquid
製造商/商標名
Upstate®
濃度
2.0 mg/mL
技術
activity assay: suitable (kinase)
NCBI登錄號
UniProt登錄號
運輸包裝
dry ice
基因資訊
human ... RB1(5925)
品質
常规评估为许多丝氨酸/苏氨酸激酶的底物。
外觀
50 mM Tris-HCl(pH 7.5),150 mM NaCl和500 mM 咪唑
儲存和穩定性
自收到之日起在-20°C可稳定保存1年。 分装保存以避免反复冻融。
法律資訊
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
訊號詞
Danger
危險聲明
危險分類
Eye Dam. 1 - Repr. 1B - Skin Corr. 1C
儲存類別代碼
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Journal of cell science, 128(1), 88-99 (2014-11-09)
In most organisms, telomeres attach to the nuclear envelope at the onset of meiosis to promote the crucial processes of pairing, recombination and synapsis during prophase I. This attachment of meiotic telomeres is mediated by the specific distribution of several
PLoS computational biology, 15(8), e1006813-e1006813 (2019-08-06)
Prediction of compounds that are active against a desired biological target is a common step in drug discovery efforts. Virtual screening methods seek some active-enriched fraction of a library for experimental testing. Where data are too scarce to train supervised
NPJ breast cancer, 8(1), 126-126 (2022-11-30)
Despite the biological and therapeutic relevance of CDK4/6 for the treatment of HR+, HER2- advanced breast cancer, the detailed mode of action of CDK4/6 inhibitors is not completely understood. Of particular interest, phosphorylation of CDK4 at T172 (pT172) is critical
Oncogene, 40(30), 4872-4883 (2021-06-24)
Cyclin D1 is an essential regulator of the G1-S cell-cycle transition and is overexpressed in many cancers. Expression of cyclin D1 is under tight cellular regulation that is controlled by many signaling pathways. Here we report that PARP14, a member
Cancer cell, 32(6), 761-776 (2017-12-13)
Most cancers preserve functional retinoblastoma (Rb) and may, therefore, respond to inhibition of D-cyclin-dependent Rb kinases, CDK4 and CDK6. To date, CDK4/6 inhibitors have shown promising clinical activity in breast cancer and lymphomas, but it is not clear which additional
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门